antibody against cdk13 (Santa Cruz Biotechnology)
Santa Cruz Biotechnology is a verified supplier 
91
Structured Review
Santa Cruz Biotechnology
antibody against cdk13
Antibody Against Cdk13, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 91/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibody+against+cdk13/Cdc2L5+Antibody/pmc10183503-100-26-29
Average 91 stars, based on 4 article reviews
Antibody Against Cdk13, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 91/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antibody+against+cdk13/Cdc2L5+Antibody/pmc10183503-100-26-29
Average 91 stars, based on 4 article reviews
antibody against cdk13 - by Bioz Stars,
2026-09
91/100 stars
Images
1) Product Images from "Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction"
Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction
Journal: Journal of Thoracic Disease
doi: 10.21037/jtd-23-437
Figure Legend Snippet: CDK13 is a downstream target gene for the oncological role of CCNO in LUAD. (A) Heatmap of mRNAs in the H1299 cell line with stable knockdown of CCNO obtained from transcriptome sequencing by hierarchical clustering, identifying that CCNO alters the expression of genes associated with the cell cycle. The signaling pathways of genes altered by CCNO knockdown in cells are detected by microarray analysis. The length of the columns represents the number of genes. (B) Potential molecules bound to Flag- CCNO are obtained by liquid-phase mass spectrometry analysis of the contents of H1299 cells stably overexpressing Flag- CCNO . The height of the column indicates the abundance value of the contents. (C) Correlation analysis of CCNO with CDK13 at the mRNA level in matched LUADs in the GEO dataset. (D) Correlation analysis of CDK13 expression with CCNO in 94 matched LUAD patients by immunohistochemical staining analysis. (E) COIP demonstrates that CDK13 and CCNO can bind to each other intracellularly. (F) Silver staining assay. (G) Immunofluorescence shows that CCNO co-localizes with CDK13 in the nucleus (blue with DAPI means nucleus, green with CCNO antibody and red with CDK13 antibody, 400×). (H) Typical IHC images of CDK13 high and low expression in LUAD and para-tumors (7× and 40×). GSVA, Gene Set Variation Analysis; CCNO , Cyclin O; LC-MS, liquid chromatography tandem mass spectrometry; TPM, transcripts per million; LUAD, lung adenocarcinoma; IgG, immunoglobulin G; GEO, Gene Expression Omnibus; IHC, immunohistochemistry; COIP, co-immunoprecipitation.
Techniques Used: Knockdown, Sequencing, Expressing, Protein-Protein interactions, Microarray, Mass Spectrometry, Stable Transfection, Immunohistochemical staining, Staining, Silver Staining, Immunofluorescence, Liquid Chromatography with Mass Spectroscopy, Liquid Chromatography, Gene Expression, Immunohistochemistry, Immunoprecipitation
Figure Legend Snippet: CCNO promotes tumor cell proliferation and survival through p-EGFR in vivo via CDK13 . (A) Changes in the expression of the EGFR biomarkers p-HER2 , HER2 , p-EGFR , EGFR , p-p70S6K , p70S6K , pAKT , and AKT after CCNO knockdown as detected by western blot. (B) Representative images of IHC staining of p-EGFR in xenograft tumors (200×). (C) CCK8 assays identify proliferation under different treatments in H1299 cells stably overexpressing CCNO . NC, negative control; OE, overexpression; CI, CCNOsi ; S, SR-4835; C, Cetuximab; P, Placebo; CET, Cetuximab; CCNO , Cyclin O; EGFR , epidermal growth factor receptor; HER2 , human epidermal growth factor receptor-2; AKT , protein kinase B; CCK8, Cell Counting Kit-8.
Techniques Used: In Vivo, Expressing, Knockdown, Western Blot, Immunohistochemistry, Stable Transfection, Negative Control, Over Expression, Cell Counting
Figure Legend Snippet: CCNO activates the p-EGFR signaling pathways via CDK13 in vitro . (A) Typical images of tumors from the different treatment groups 5 weeks after tumor injections. (B,C) The weights (B) and volumes (C) are lower in xenograft tumors with overexpressed CCNO under different treatments. *, P<0.05; **, P<0.01; ****, P<0.0001. NC, negative control; OE, overexpression; SR, SR-4835; S, SR-4835; C, Cetuximab; ns, no significance; CCNO , Cyclin O.
Techniques Used: Protein-Protein interactions, In Vitro, Negative Control, Over Expression
Figure Legend Snippet: CDK13 is a key factor in the oncological effect of CCNO . (A) CCK8 assays identify proliferation under different treatments in H1299 and A549 cells. (B) EdU assays (400×) identify proliferation under different treatments in H1299 and A549 cells. **, P<0.01; ***, P<0.001; ****, P<0.0001. CCK8, Cell Counting Kit-8; NC, negative control; ns, no significance; CCNO si, CCNO knockdown; CCNO , Cyclin O; EdU, 5-Ethynyl-2'-deoxyuridine.
Techniques Used: Cell Counting, Negative Control, Knockdown
Related Articles
Knockdown:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Sequencing:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Expressing:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Protein-Protein interactions:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Microarray:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Mass Spectrometry:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Stable Transfection:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Immunohistochemical staining:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Staining:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Silver Staining:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Immunofluorescence:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Liquid Chromatography with Mass Spectroscopy:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Liquid Chromatography:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Gene Expression:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Immunohistochemistry:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Immunoprecipitation:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), In Vivo:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Western Blot:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Negative Control:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Over Expression:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), Cell Counting:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), In Vitro:Article Title: Cyclin O promotes lung cancer progression and cetuximab resistance via cell cycle regulation and CDK13 interaction Article Snippet: The following antibodies were used: antibody against CCNO (Abcam Cat#ab47682), antibody against HER-2 (Abcam Cat#ab214275), antibody against EGFR (Abcam Cat#52894), antibody against beta Actin (Invitrogen Cat#MA1-140), |